Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox

26 June 2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published new technology appraisals, updating on its previous decisions announced earlier this year.

The agency says that no appeals were received against the final draft guidance on erlotinib (Tarceva, from Roche; ROG: SIX), lapatinib (Tyverb, from GlaxoSmithKline: LSE: GSK) and trastuzumab (Herceptin, also from Roche), abiraterone (Zytiga, from Janssen, a Johnson & Johnson unit; NYSE: JNJ) or botulinum toxin type A (Botox, from Allergan; NYSE: AGN), therefore the recommendations have not changed and the guidance is now being issued to the National Health Service.

Zytiga is recommended in combination with prednisone or prednisolone as a treatment option for castration-resistant metastatic prostate cancer that has progressed on or after one docetaxel-containing therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK